Flibanserin is prescribed to treat premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD), which is characterized by low sexual desire that causes noticeable distress or interpersonal difficulty and is not brought on by any of the following: problems in the relationship, co-occurring medical or psychiatric conditions, relationship issues, or side effects from medication or other drugs.
🛒 How to order this item?
100% Genuine Products, Guaranteed
Safe & Secure Payments, Always
Fast, Secure & Efficient Delivery
Proper Packaging
Show More
Fliban 100mg Tablet is indeed a medication used to treat hypoactive sexual desire disorder (HSDD) in premenopausal women. HSDD is characterized by a persistent or recurrent lack of sexual desire that causes distress or interpersonal difficulties. Flibanserin is specifically indicated for women who have not gone through menopause and experience low sexual desire that is bothersome to them.
It's important to note that flibanserin should not be used by women who have already gone through menopause or by men. Additionally, it is crucial to understand that this medication is not intended for enhancing sexual performance or addressing sexual problems caused by medical or mental conditions, relationship issues, or substance use.
Since Fliban is a prescription medication, it is only available through a doctor's prescription. If you believe you may benefit from this medication, it's advisable to consult with a healthcare professional who can evaluate your condition and determine if flibanserin is a suitable treatment option for you. They will consider your medical history, symptoms, and any potential interactions or contraindications before prescribing the medication.
Avoid alcohol when you take Fliban 100mg Tablet
During pregnancy, Fliban 100mg Tablet should be used only when clearly needed
There are no adequate studies on women for determining infant risk when using this medication during breastfeeding. Weigh the potential benefits against the potential risks before taking this medication while breastfeeding.
Do not drive, operate machinery, or do things that require clear thinking until at least 6 hours after you take Fliban 100mg Tablet
Fliban 100mg Tablet should be used with caution in patients with kidney disease. A dose adjustment of Fliban 100mg Tablet may be needed. Please consult your doctor. The use of Fliban 100mg Tablet is not recommended in patients with severe kidney disease.
Fliban 100mg tablets should be used with caution in patients with liver disease. A dose adjustment of Fliban 100mg Tablet may be needed. Please consult your doctor. The use of Fliban 100mg Tablet is not recommended in patients with severe liver disease.
Flibanserin is in a class of medications called a serotonin receptor 1A agonist/serotonin receptor 2A antagonist. It works by changing the activity of serotonin and other natural substances in the brain.
Fliban 100mg Tablet is a prescription medicine used to treat hypoactive (low) sexual desire disorder (HSDD) in women who have not gone through menopause, who have not had problems with low sexual desire in the past, and who have low sexual desire no matter the type of sexual activity, the situation, or the sexual partner. Women with HSDD have a low sexual desire which is troubling to them. Their low sexual desire is not due to:
Fliban 100mg Tablet is not for use for the treatment of HSDD in women who have gone through menopause, in men, or in children.
Fliban 100mg Tablet is not for use to enhance sexual performance.
Flibanserin, the active ingredient in Addyi, has a complex mechanism of action that involves multiple receptor interactions in the brain. It acts as a postsynaptic serotonin-1A (5HT-1A) receptor agonist and a 5HT-2A receptor antagonist. Additionally, it has moderate antagonist activities at the 5-HT2B, 5-HT2C, and dopamine D4 receptors.
The exact mechanism by which flibanserin treats hypoactive sexual desire disorder (HSDD) is not fully understood. However, it is believed to work by restoring the balance of certain neurotransmitters in the brain, particularly in the prefrontal cortex, which is involved in the brain's motivation and reward systems.
One proposed theory suggests that flibanserin may enhance sexual desire by increasing dopamine and norepinephrine levels while transiently reducing serotonin levels in the prefrontal cortex. Modulating these neurotransmitters, it is thought to facilitate the prefrontal cortex's control over the brain's motivation and reward structures, thereby allowing sexual desire to manifest.
Flibanserin's effects on neurotransmitters may also involve reduced glutamate transmission, although the exact details of this interaction are not fully understood.
It's important to note that our understanding of flibanserin's mechanism of action is still evolving, and further research is needed to gain a comprehensive understanding of how it specifically addresses HSDD.
Medicines not recommended for use with flibanserin:
Medicines usually not recommended for use with flibanserin but may be required in some cases with dose adjustments:
Medicines that may have increased side effects but may still be used together with flibanserin:
Additionally, it is recommended to avoid consuming grapefruit juice while taking flibanserin.
Regarding the use of flibanserin during pregnancy, there is a lack of studies on pregnant women to determine the potential risks associated with its use. Animal studies have shown that fetal toxicity occurred only when there was significant maternal toxicity, including reduced weight gain and sedation. Adverse effects on reproduction and development in animals included decreased fetal weight, structural abnormalities, and increased fetal loss at exposures higher than 15 times the recommended human dosage.
The distribution of flibanserin in human breast milk is unknown, but it has been found to be excreted in rat milk. It is unclear whether flibanserin has any effects on the breastfed infant or affects milk production. Due to the potential for serious adverse reactions, including sedation, in a breastfed infant, breastfeeding is not recommended while undergoing treatment with flibanserin.
If you are pregnant, planning to become pregnant, or breastfeeding, it is essential to discuss the potential risks and benefits of using flibanserin with your healthcare provider. They can provide you with personalized advice based on your specific situation and help you make an informed decision about the use of this medication.
Coadministration of flibanserin with alcohol is strongly discouraged, as it significantly increases the risk of severe hypotension (low blood pressure) and syncope (fainting). This warning is also mentioned in the contraindications and black box warnings associated with flibanserin. The combination of flibanserin and alcohol can lead to enhanced central nervous system (CNS) depression, resulting in symptoms such as somnolence (sleepiness) and sedation. It is crucial to avoid alcohol consumption while taking flibanserin to minimize these risks.
Similarly, the coadministration of moderate or strong CYP3A4 inhibitors with flibanserin can significantly increase the concentrations of flibanserin in the body. This can also lead to hypotension and syncope. Therefore, it is important to inform your doctor about all medications you are taking, including prescription drugs, over-the-counter medications, herbal supplements (such as ginkgo and resveratrol), and nonprescription drugs (such as cimetidine) that may have weak CYP3A4 inhibitory effects. This will help your doctor assess any potential risks and make appropriate adjustments to your treatment plan.
Flibanserin can cause CNS depression, and the risk of such depression is increased when taken during waking hours, with alcohol or other CNS depressants, or with medications that increase flibanserin concentrations (such as CYP3A4 inhibitors). It is important to be cautious while taking flibanserin and avoid activities that require mental alertness, such as driving or operating machinery, especially if experiencing somnolence or sedation.
Regarding lactation, it is unknown whether flibanserin is distributed in human breast milk. However, it has been found to be excreted in rat milk. Due to the potential for serious adverse reactions, including sedation, in breastfed infants, breastfeeding is not recommended during treatment with flibanserin. It is important to discuss breastfeeding considerations with your healthcare provider before starting flibanserin.
It is crucial to carefully follow your doctor's instructions, read the medication's contraindications, warnings, and dosing information, and consult with your healthcare provider regarding any concerns or questions you may have about flibanserin and its potential interactions or effects.
Keep the temperature below 30°C and away from light and moisture. Keep out of children's reach.
Disclaimer:
ePharma sole intention is to ensure that its consumers get proper
information as musch as possible. Although we do not guarantee the
accuracy and the completeness of the information that provided and
here information is for informational purposes only.
The information contained herein should NOT be used as a substitute
for the advice of a qualified physician. This may not cover
everything about particular health conditions,
lab tests, medicines, all possible side effects, drug interactions,
warnings, alerts, etc. Please consult your healthcare professional
and discuss all your queries related to any disease or medicine. We
intend to support, not replace, the doctor-patient relationship.